Rare Diseases

All Conditions

Inflammatory Myofibroblastic Tumor

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Crizotinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.

Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.

Treatment With Crizotinib Single Patient Expanded Access IND 134375

Pfizer

Jean M. Tersak, M.D.

Associate Professor

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Blood and Lymph Conditions

Immune System Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Lymphoma

Lymphoma, Large-Cell, Anaplastic

Lymphosarcoma

Anaplastic Large Cell Lymphoma

crizotinib

Pfizer CT.gov Call Center

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

Participants not previously enrolled or who have discontinued study treatment or safety follow-up in a current Pfizer sponsored crizotinib clinical study are not eligible for participation in this continuation study.

Crizotinib Continuation Clinical Study

CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Safety data collection in this study will permit further characterization of the safety profile of crizotinib.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Treatment With Crizotinib Single Patient Expanded Access IND 134375	NCT03085186	Inflammatory My...	Crizotinib	2 Years - 2 Years	University of Pittsburgh
Crizotinib Continuation Clinical Study	NCT05160922	NSCLC ALCL IMT	crizotinib	1 Year - 99 Years	Pfizer
Treatment With Crizotinib Single Patient Expanded Access IND 134375	NCT03085186	Inflammatory My...	Crizotinib	2 Years - 2 Years	University of Pittsburgh
Crizotinib Continuation Clinical Study	NCT05160922	NSCLC ALCL IMT	crizotinib	1 Year - 99 Years	Pfizer
Crizotinib Continuation Clinical Study	NCT05160922	NSCLC ALCL IMT	crizotinib	1 Year - 99 Years	Pfizer

Spots Global Cancer Trial Database for inflammatory myofibroblastic tumour